In vitro Study of SPIONs-C595 as Molecular Imaging Probe for Specific Breast Cancer (MCF-7) Cells Detection
Authors
Abstract:
Background: Magnetic resonance imaging (MRI) plays an essential role in molecular imaging by delivering the contrast agent into targeted cancer cells. The aim of this study was to evaluate the C595 monoclonal antibody-conjugated superparamagnetic iron oxide nanoparticles (SPIONs-C595) for the detection of breast cancer cell (MCF-7). Methods: The conjugation of monoclonal antibody and nanoparticles was confirmed using X-ray diffraction, transmission electron microscopy, and photon correlation spectroscopy. The selectivity of the nanoprobe for breast cancer cells (MCF-7) was obtained by Prussian blue, atomic emission spectroscopy, and MRI relaxometry. Results: The in vitro MRI showed that T2 relaxation time will be reduced 76% when using T2-weighed magnetic resonance images compared to the control group (untreated cells) at the dose of 200 μg Fe/ml, as the optimum dose. In addition, the results showed the high uptake of nanoprobe into MCF-7 cancer cells. Conclusion: The SPIONs-C595 nanoprobe has potential for the detection of specific breast cancer.
similar resources
Gadolinium-Diethylenetriaminepenta-Acetic acid Conjugated with Monoclonal Antibody C595 as New Magnetic Resonance Imaging Contrast Agents for Breast Cancer (MCF-7) Detection
Background: The monoclonal antibody, C595, against breast cancer cell line was conjugated with cyclic anhydride gadolinium-diethylenetriaminepenta-acetic acid (Gd-cDTPAa) to produce Gd-DTPA-C595 and used as specific breast cancer cell line (MCF-7) contrast agents in magnetic resonance imaging (MRI). Methods: After incubation of breast cancer cell line (MCF-7), with different contrast agents (G...
full textgadolinium-diethylenetriaminepenta-acetic acid conjugated with monoclonal antibody c595 as new magnetic resonance imaging contrast agents for breast cancer (mcf-7) detection
background: the monoclonal antibody, c595, against breast cancer cell line was conjugated with cyclic anhydride gadolinium-diethylenetriaminepenta-acetic acid (gd-cdtpaa) to produce gd-dtpa-c595 and used as specific breast cancer cell line (mcf-7) contrast agents in magnetic resonance imaging (mri). methods: after incubation of breast cancer cell line (mcf-7), with different contrast agents (g...
full textDetection of MUC1-Expressing Ovarian Cancer by C595 Monoclonal Antibody-Conjugated SPIONs Using MR Imaging
The aim of this study is to find out the development and application of MUC1-expressing ovarian cancer (OVCAR3) by C595 monoclonal antibody-conjugated superparamagnetic iron oxide nanoparticles (SPIONs) using MR imaging. At the end, its use as a nanosized contrast agent MR imaging probe for ovarian cancer detection was investigated. The strategy is to use SPIONs attached to C595 mAb that binds ...
full textP-195: Thymoquinone Increases Efficacy of Tamoxifen Induced Apoptosis in Human Breast Cancer MCF-7 Cells: In Vitro
Background: The objective of this study is to evaluate combined effect of Thymoquinone (The main active component of black seeds) with Tamoxifen drug on apoptosis of human breast cancer MCF-7 cells (Noninvasive human breast cancer cell line, estrogen receptor positive). Materials and Methods: The human breast cancer MCF- 7 cells were treated with Tamoxifen (2 μM) alone or in combination with Th...
full textMagnetic Iron Oxide Nanoparticles as T2 MR Imaging Contrast Agent for Detection of Breast Cancer (MCF-7) Cell
BACKGROUND Advances of nanotechnology have led to the development of nano-materials with both potential diagnostic and therapeutic applications. Among them, Super Paramagnetic Iron Oxide Nanoparticles (SPIONs) have received particular attention. Modified EDC coupling fraction was used to fabricate the SPION-C595 as an MR imaging contrast agent for breast cancer detection in early stages. METH...
full textMy Resources
Journal title
volume 21 issue 6
pages 360- 368
publication date 2017-11
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023